Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials

Journal of Neuro-Oncology

Volumn 123, Issue 2, 2015, Pages 251-257

  Carlson, Julie A ^a,c   Reddy, Krishna ^b   Gaspar, Laurie E ^a   Ney, Douglas ^a   Kavanagh, Brian D ^a   Damek, Denise ^a   Lillehei, Kevin ^a   Chen, Changhu ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c NONE   (United States)

Author keywords

Bevacizumab; GBM; Glioblastoma multiforme; Intensity modulated radiation therapy

Indexed keywords

BEVACIZUMAB; CARMUSTINE; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADULT; AGED; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN TISSUE; HYPOFRACTIONATED INTENSITY MODULATED RADIATION THERAPY; INSOMNIA; INTENSITY MODULATED RADIATION THERAPY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REOPERATION; SEIZURE; STEREOTACTIC RADIOSURGERY; TUMOR BIOPSY; TUMOR VOLUME; WOUND DEHISCENCE; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIATION DOSE FRACTIONATION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE;

EID: 84930377853     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1791-4     Document Type: Article

References (28)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
3. Chen C, Damek D, Gaspar LE et al (2011) Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 81:1066–1074
4. Reddy K, Damek D, Gaspar LE et al (2012) Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 84:655–660
5. Reddy K, Gaspar LE, Kavanagh BD et al (2014) Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. J Med Imaging Radiat Oncol 58:714–721
6. Birner P, Piribauer M, Fischer I et al (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143
7. Godard S, Getz G, Delorenzi M et al (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:6613–6625
8. Stefanik DF, Fellows WK, Rizkalla LR et al (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55:91–100
9. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844
10. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745
11. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729
12. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
13. Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380
14. Gutin PH, Iwamoto FM, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163
15. Ney D, Carlson JA, Damek DM et al (2015) Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. J Neurooncol 122:135–143
16. Gonzalez J, Kumar AJ, Conrad CA et al (2007) Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67:323–326
17. Torcuator R, Zuniga R, Mohan YS et al (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94:63–68
18. Wong ET, Huberman M, Lu XQ et al (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26:5649–5650
19. Salmaggi A, Eoli M, Frigerio S et al (2003) Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62:297–303
20. Lamszus K, Ulbricht U, Matschke J et al (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399–1405
21. Coderre JA, Morris GM, Micca PL et al (2006) Late effects of radiation on the central nervous system: role of vascular endothelial damage and glial stem cell survival. Radiat Res 166:495–503
22. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722
23. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708
24. Minniti G, Clarke E, Lanzetta G et al (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48
25. Blonigen BJ, Steinmetz RD, Levin L et al (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77:996–1001
26. Omuro A, Beal K, Gutin P et al (2014) Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res 20:5023–5031
27. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62
28. Jeyaretna DS, Curry WT Jr, Batchelor TT et al (2011) Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 29:e159–e162